THE USE OF HISTORICAL CONTROLS IN DEVICE STUDIES Vic Hasselblad Duke Clinical Research Institute.

Slides:



Advertisements
Similar presentations
Bayes rule, priors and maximum a posteriori
Advertisements

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Sep. 16, 2005 Lilly Yue, Ph.D.* CDRH, FDA, Rockville MD * No official support.
ISSUES THAT PLAGUE NON- INFERIORITY TRIALS PAST AND FUTURE RALPH B. DAGOSTINO, SR. BOSTON UNIVERSITY HARVARD CLINICAL RESEARCH INSTITUTE.
The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,
Sampling Design, Spatial Allocation, and Proposed Analyses Don Stevens Department of Statistics Oregon State University.
Multivariate Meta-analysis: Notes on Correlations Robert Platt Department of Epidemiology & Biostatistics McGill University Jack Ishak United BioSource.
Multiple-choice question
1 Contact details Colin Gray Room S16 (occasionally) address: Telephone: (27) 2233 Dont hesitate to get in touch.
How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
1 Analyzing HIV Prevalence Trends from Antenatal Clinic (ANC) Sentinel Surveillance Data and Serosurveillance Data from High Risk Groups* Ray Shiraishi.
Study Size Planning for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
T-tests continued.
A workshop introducing doubly robust estimation of treatment effects
Departments of Medicine and Biostatistics
Statistical Decision Making
Sensitivity Analysis for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Point estimation, interval estimation
Clustered or Multilevel Data
Meta-analysis & psychotherapy outcome research
= == Critical Value = 1.64 X = 177  = 170 S = 16 N = 25 Z =
7-1 Introduction The field of statistical inference consists of those methods used to make decisions or to draw conclusions about a population. These.
Sample Size Determination Ziad Taib March 7, 2014.
Basic Analysis of Variance and the General Linear Model Psy 420 Andrew Ainsworth.
Are the results valid? Was the validity of the included studies appraised?
Dr. Abdulaziz BinSaeed & Dr. Hayfaa A. Wahabi Department of Family & Community medicine  Case-Control Studies.
Department of O UTCOMES R ESEARCH. Daniel I. Sessler, M.D. Michael Cudahy Professor and Chair Department of O UTCOMES R ESEARCH The Cleveland Clinic Clinical.
Proximal Protection during Saphenous Vein Graft Intervention using the Proxis™ Embolic Protection System The PROXIMAL Trial Laura Mauri, MD, MSc, FACC,
PARAMETRIC STATISTICAL INFERENCE
1 Sampling Distributions Lecture 9. 2 Background  We want to learn about the feature of a population (parameter)  In many situations, it is impossible.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Chapter 1 Measurement, Statistics, and Research. What is Measurement? Measurement is the process of comparing a value to a standard Measurement is the.
Chapter 7 Point Estimation
Testing Hypotheses about Differences among Several Means.
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
Case Control Study Dr. Ashry Gad Mohamed MB, ChB, MPH, Dr.P.H. Prof. Of Epidemiology.
Medical Statistics as a science
Introduction Sample Size Calculation for Comparing Strategies in Two-Stage Randomizations with Censored Data Zhiguo Li and Susan Murphy Institute for Social.
© 2011 Cengage Learning. All Rights Reserved. May not be copied, scanned, or duplicated, in whole or in part, except for use as permitted in a license.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
1 Multivariable Modeling. 2 nAdjustment by statistical model for the relationships of predictors to the outcome. nRepresents the frequency or magnitude.
Comparison of groups The purpose of analysis is to compare two or more population means by analyzing sample means and variances. One-way analysis is used.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.
One-Way Analysis of Variance Recapitulation Recapitulation 1. Comparing differences among three or more subsamples requires a different statistical test.
 An exposure-response (E-R) analysis in oncology aims at describing the relationship between drug exposure and survival and in addition aims at comparing.
Handout Six: Sample Size, Effect Size, Power, and Assumptions of ANOVA EPSE 592 Experimental Designs and Analysis in Educational Research Instructor: Dr.
Comparing Means Chapter 24. Plot the Data The natural display for comparing two groups is boxplots of the data for the two groups, placed side-by-side.
Analytical Studies Case – Control Studies By Dr. Sameh Zaytoun (MBBch, DPH, DM, FRCP(Manch), DTM&H(UK),Dr.PH) University of Alexandria - Egypt Consultant.
(ARM 2004) 1 INNOVATIVE STATISTICAL APPROACHES IN HSR: BAYESIAN, MULTIPLE INFORMANTS, & PROPENSITY SCORES Thomas R. Belin, UCLA.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Disclosures Runlin Gao has received a research grant
Step 1: Specify a null hypothesis
Runlin Gao, M.D. On behalf of ABSORB China Investigators
on behalf of the ABSORB II Investigators
Chapter 23 Comparing Means.
OHDSI Method Evaluation
Donald E. Cutlip, MD Beth Israel Deaconess Medical Center
Mark Rothmann U.S. Food and Drug Administration September 14, 2018
Sections 6-4 & 7-5 Estimation and Inferences Variation
Comparing Populations
REALITY: 8 month results
Warmup To check the accuracy of a scale, a weight is weighed repeatedly. The scale readings are normally distributed with a standard deviation of
BASKET-SAVAGE Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were.
Chapter 24 Comparing Means Copyright © 2009 Pearson Education, Inc.
Gregg W. Stone, MD Columbia University Medical Center
Long Term Clinical Results from the Endeavor Program: 5-Year Follow up
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Atlantic Cardiovascular Patient Outcomes Research Team
Presentation transcript:

THE USE OF HISTORICAL CONTROLS IN DEVICE STUDIES Vic Hasselblad Duke Clinical Research Institute

HISTORICAL CONTROLS: THE SETTING New trial will have a single experimental arm The endpoint is dichotomous Comparison will be to either summary rates from other studies another single arm using patient level analyses

HISTORICAL CONTROLS NO PATIENT LEVEL DATA Each historical arm has to be treated as a sample Results are usually calculated from a random effects model The distribution for the next sample is estimated This requires that the between study variance be estimated specifically

AN EXAMPLE FROM DISTAL PROTECTION DEVICES A new distal protection device proposed using data from existing distal protection devices as historical controls The endpoint was major adverse cardiac events (MACE) The results from these three arms appeared to be very consistent The estimation proved difficult (as we shall see)

DISTAL PROTECTION DEVICES

FilterWire (FIRE Trial) GuardWire (FIRE Trial) GuardWire (SAFER Trial) MACE Rate at 30 Days DISTAL PROTECTION DEVICES

The prior for the mean rate was a non- informative (Jeffries) prior The prior for the study-to-study variation (τ 2 ) was assumed to be non- informative (1/τ 2 ) The expected distribution of the log-odds of the event rate was assumed to be normal CONSTRUCTING A HIERARCHICAL BAYES RANDOM EFFECTS MODEL

POSTERIOR FOR VARIANCE (τ 2 )

POSTERIOR FOR MEAN RATE

In order to use the results from a small number of arms, one has to assume that the variation between arms is quite small. In other words, one has to add subjective information to the prior. CONCLUSIONS FOR HISTORICAL CONTROLS NO PATIENT LEVEL DATA

HISTORICAL CONTROLS WITH PATIENT LEVEL DATA Propensity scores are used to correct for the fact that the two populations are not guaranteed to be similar Patients are stratified by their propensity to get a particular treatment Patients within a given propensity score are compared and the results are pooled across propensity categories

AN EXAMPLE WITH STENTS The object was to compare two different stent methodologies, one of which was a historical one The safety endpoint was MACE at 30 days The comparison was based on non-inferiority Propensity scores were used to make the comparison: two different models were used as a sensitivity analysis

FIRST PROPENSITY SCORE Used vessel diameter, lesion length, and presence of diabetes as predictors. SECOND PROPENSITY SCORE Used vessel diameter, lesion length, presence of diabetes plus several others factors including smoking and EF as predictors.

AN EXAMPLE WITH STENTS First propensity score Second propensity score Delta

Percent Bias in the Estimated Treatment Effect Based on a Stratified Propensity Score (from Lunceford and Davidian, 2004) STRATIFIED PROPENSITY SCORES CAN HAVE DIFFICULTIES

Ratio of Means Squared Errors Stratified Propensity Score Versus Doubly Robust Estimator (from Lunceford and Davidian, 2004) STRATIFIED PROPENSITY SCORES CAN HAVE DIFFICULTIES

HISTORICAL CONTROLS WITH PATIENT LEVEL DATA Even with the use of propensity scores, the results of a historical control analysis may not be definitive The use of stratified propensity scores is not always the solution In certain situations doubly robust estimators are better as long as they have the correct model (for propensity or risk) If the models are wrong, all bets are off

SUMMARY Historical control analyses are fraught with difficulties In many cases you dont know if problems exist until after the data have been collected